Weekly shot may halt arthritis progression in kids
NCT ID NCT03841357
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a weekly injection of abatacept (Orencia) plus usual care could prevent juvenile idiopathic arthritis (JIA) from spreading to more joints or causing eye inflammation. 121 children with recent-onset JIA affecting 4 or fewer joints took part. The goal was to see if 24 weeks of treatment could keep the disease from becoming more severe over 18 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Abatacept (Orencia) injection
What this could lead to
If successful, this could offer a way to stop early-stage juvenile arthritis from becoming more severe, reducing the need for stronger medications.
What could go wrong
This is a completed Phase 3 trial, but results may not apply to all children. Abatacept can increase infection risk and other side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for JUVENILE IDIOPATHIC ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
-
Children's Hospital at Montefiore/ Albert Einstein University Hospital
The Bronx, New York, 10461, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
MetroHealth System
Cleveland, Ohio, 44109, United States
-
Monroe Carell Jr Children's Hospital at Vanderbilt
Nashville, Tennessee, 37232, United States
-
Nationwide Children's Hospital
Columbus, Ohio, 43205, United States
-
Riley Hospital for Children at Indiana University Health
Indianapolis, Indiana, 46202, United States
-
Seattle Children's Hospital
Seattle, Washington, 98105, United States
-
Shands at the University of Florida
Gainesville, Florida, 32610, United States
-
The Children's Hospital Colorado
Aurora, Colorado, 80045, United States
-
University of California at San Francisco Medical Center
San Francisco, California, 94143, United States
-
University of Iowa Hospitals of Clinics
Iowa City, Iowa, 52242, United States
-
University of Louisville School of Medicine/ Norton Charities Pediatric Clinical Research Unit
Louisville, Kentucky, 40202, United States
-
University of Minnesota; Children's Hospital and Clinics of Minnesota
Minneapolis, Minnesota, 55454, United States
-
University of North Carolina
Chapel Hill, North Carolina, 27514, United States
-
University of Utah
Salt Lake City, Utah, 84158, United States